British Society for Haematology guidelines for the management of adult myelodysplastic syndromes
暂无分享,去创建一个
G. Mufti | M. Raghavan | S. Stanworth | S. Killick | D. Bowen | A. Sternberg | H. Enright | W. Ingram | C. Cargo | Gail L. Jones | J. Kell | J. Mills | Elspeth M. Payne | A. Kulasekararaj | D. Wiseman | L. Quek | D. Culligan | P. Krishnamurthy | S. Green | G. Jones
[1] A. Gennery,et al. Guidelines on the use of irradiated blood components , 2020, British journal of haematology.
[2] E. Wood,et al. Red cell transfusion in outpatients with myelodysplastic syndromes: a feasibility and exploratory randomised trial , 2020, British journal of haematology.
[3] M. Cazzola,et al. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. , 2020, The New England journal of medicine.
[4] Benjamin L. Ebert,et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes , 2019, Nature Medicine.
[5] U. Germing,et al. Comparison between Upfront Transplantation and different Pretransplant Cytoreductive Treatment Approaches in Patients with High-Risk Myelodysplastic Syndrome and Secondary Acute Myelogenous Leukemia. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[6] A. Savic,et al. Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry , 2019, Haematologica.
[7] M. Cazzola,et al. Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome , 2019, Leukemia.
[8] P. Greenberg,et al. Clinical effectiveness and safety of erythropoietin‐stimulating agents for the treatment of low‐ and intermediate‐1−risk myelodysplastic syndrome: a systematic literature review , 2018, British journal of haematology.
[9] A. Verma,et al. Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia. , 2018, Blood.
[10] N. Kröger,et al. Relative Impact of HLA Matching and Non-HLA Donor Characteristics on Outcomes of Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome. , 2018, Biology of Blood and Marrow Transplantation.
[11] R. Schlenk,et al. Prospective Multicenter Phase 3 Study Comparing 5-Azacytidine (5-Aza) Induction Followed By Allogeneic Stem Cell Transplantation Versus Continuous 5-Aza According to Donor Availability in Elderly MDS Patients (55-70 years) (VidazaAllo Study) , 2018, Blood.
[12] C. Flowers,et al. Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] S. Fallahpour,et al. Azacitidine in the ‘real‐world’: an evaluation of 1101 higher‐risk myelodysplastic syndrome/low blast count acute myeloid leukaemia patients in Ontario, Canada , 2018, British journal of haematology.
[14] K. Götze,et al. Enhanced labile plasma iron and outcome in acute myeloid leukaemia and myelodysplastic syndrome after allogeneic haemopoietic cell transplantation (ALLIVE): a prospective, multicentre, observational trial. , 2018, The Lancet. Haematology.
[15] K. Götze,et al. A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS , 2018, Leukemia.
[16] M. Konopleva,et al. Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms , 2018, Oncotarget.
[17] A. Nagler,et al. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial. , 2018, The Lancet. Haematology.
[18] D. Swinkels,et al. Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes , 2017, Haematologica.
[19] E. Wood,et al. Red cell alloimmunization is associated with development of autoantibodies and increased red cell transfusion requirements in myelodysplastic syndrome , 2017, Haematologica.
[20] B. Leber,et al. ITACA: A new validated international erythropoietic stimulating agent‐response score that further refines the predictive power of previous scoring systems , 2017, American journal of hematology.
[21] K. Kreuzer,et al. Thrombopoietin mimetics for patients with myelodysplastic syndromes. , 2017, The Cochrane database of systematic reviews.
[22] M. Delforge,et al. A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes , 2017, Leukemia.
[23] R. Larson,et al. Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long‐term safety and efficacy , 2017, British journal of haematology.
[24] E. Wood,et al. Red cell transfusion thresholds in myelodysplastic syndromes: a clinician survey to inform future clinical trials , 2017, Internal medicine journal.
[25] N. Kröger,et al. Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial). , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] S. Miyano,et al. Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation. , 2017, Blood.
[27] A. Ganser,et al. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. , 2017, Blood.
[28] A. Stamatoullas,et al. Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] C Pascutto,et al. Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System , 2017, Leukemia.
[30] A. Stamatoullas,et al. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. , 2017, The Lancet. Haematology.
[31] E. Leifer,et al. Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] D. Neuberg,et al. Prognostic Mutations in Myelodysplastic Syndrome after Stem‐Cell Transplantation , 2017, The New England journal of medicine.
[33] H. Garelius,et al. Erythropoiesis‐stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower‐risk myelodysplastic syndrome , 2016, Journal of internal medicine.
[34] D. Neuberg,et al. Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations , 2016, Haematologica.
[35] H. Einsele,et al. Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[36] R. Bellazzi,et al. Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] Alan M. Miller,et al. Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] N. Kröger,et al. Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMT , 2016, Annals of Hematology.
[39] M. Cazzola,et al. Time-dependent changes in mortality and transformation risk in MDS. , 2016, Blood.
[40] E. Roman,et al. Myeloid malignancies in the real-world: Occurrence, progression and survival in the UK’s population-based Haematological Malignancy Research Network 2004–15 , 2016, Cancer epidemiology.
[41] O. Visser,et al. Red-blood-cell alloimmunisation in relation to antigens' exposure and their immunogenicity: a cohort study. , 2016, The Lancet. Haematology.
[42] Mario Cazzola,et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.
[43] S. Nahas,et al. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes , 2016, Leukemia.
[44] P. Vyas,et al. Alternative agents versus prophylactic platelet transfusion for preventing bleeding in patients with thrombocytopenia due to chronic bone marrow failure: a network meta-analysis and systematic review. , 2016, The Cochrane database of systematic reviews.
[45] Inderjeet Dokal,et al. Guidelines for the diagnosis and management of adult aplastic anaemia , 2016, British journal of haematology.
[46] R. Fulton,et al. TP 53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes , 2016 .
[47] M. Tormo,et al. Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry , 2015, Leukemia.
[48] H. Kantarjian,et al. Outcome of patients with low‐risk and intermediate‐1‐risk myelodysplastic syndrome after hypomethylating agent failure: A report on behalf of the MDS Clinical Research Consortium , 2015, Cancer.
[49] Benjamin Djulbegovic,et al. Platelet Transfusion: A Clinical Practice Guideline From the AABB , 2015, Annals of Internal Medicine.
[50] T. Haferlach,et al. Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia , 2014, Haematologica.
[51] D. Neuberg,et al. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] C. Preudhomme,et al. Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine. , 2014, Leukemia research.
[53] M. Tormo,et al. Multivariate time‐dependent comparison of the impact of lenalidomide in lower‐risk myelodysplastic syndromes with chromosome 5q deletion , 2014, British Journal of Haematology.
[54] M. Vignetti,et al. Deferasirox for transfusion‐dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial) , 2014, European journal of haematology.
[55] W. Wiktor-Jedrzejczak,et al. Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1–risk myelodysplastic syndrome and thrombocytopenia , 2014, Cancer.
[56] P. Vyas,et al. Guidelines for the diagnosis and management of adult myelodysplastic syndromes , 2014, British journal of haematology.
[57] B. Skikne,et al. Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS , 2013, Leukemia.
[58] M. Cazzola,et al. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[59] Stefano Guidi,et al. Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome , 2013, American journal of hematology.
[60] G. Mann,et al. Ferritin concentrations correlate to outcome of hematopoietic stem cell transplantation but do not serve as biomarker of graft-versus-host disease , 2013, Annals of Hematology.
[61] G. Mufti,et al. TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis , 2013, British journal of haematology.
[62] P. Greenberg,et al. A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine , 2013, Leukemia & lymphoma.
[63] C. Milkins,et al. Guidelines for pre‐transfusion compatibility procedures in blood transfusion laboratories , 2013, Transfusion medicine.
[64] A. Glasmacher,et al. Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis , 2012, Leukemia.
[65] R. Larson,et al. A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide , 2012, Journal of Hematology & Oncology.
[66] A. Duhamel,et al. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[67] Luca Malcovati,et al. Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.
[68] S. Berendse,et al. Prevention and management of neutropenic sepsis in patients with cancer: summary of NICE guidance , 2012, BMJ : British Medical Journal.
[69] P. Fenaux,et al. Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes , 2012, Haematologica.
[70] U. Germing,et al. Improved survival in MDS patients receiving iron chelation therapy - a matched pair analysis of 188 patients from the Düsseldorf MDS registry. , 2012, Leukemia research.
[71] D. Steensma,et al. Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[72] S. Chevret,et al. Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies , 2012, Haematologica.
[73] R. Schlenk,et al. Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study , 2012, Leukemia.
[74] S. Fröhling,et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. , 2012, Blood.
[75] M. Cazzola,et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. , 2011, Blood.
[76] M. Cazzola,et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS) , 2011, Haematologica.
[77] J. Astermark,et al. Quality of life, physical function and MRI T2* in elderly low‐risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusions , 2011, European journal of haematology.
[78] J. Maciejewski,et al. Perceptions of disease state, treatment outcomes, and prognosis among patients with myelodysplastic syndromes: results from an internet-based survey. , 2011, The oncologist.
[79] Eva Hellström-Lindberg,et al. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[80] N. Kröger,et al. Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosis , 2011, Haematologica.
[81] A. Stamatoullas,et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. , 2011, Blood.
[82] G. Mufti,et al. Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes. , 2010, Critical reviews in oncology/hematology.
[83] A. Stamatoullas,et al. Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: a retrospective analysis on 112 patients. , 2010, Leukemia research.
[84] W. Hofmann,et al. Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion. , 2010, Leukemia research.
[85] A. Ganser,et al. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. , 2010, Leukemia research.
[86] M. Laouri,et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[87] G. Mufti,et al. Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[88] R. Larson,et al. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[89] Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group , 2010, International journal of hematology.
[90] J. Issa,et al. Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high‐risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities , 2009, Cancer.
[91] H. Kantarjian,et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[92] L. Malcovati,et al. Clinical relevance of extra-hematologic comorbidity in the management of patients with myelodysplastic syndrome , 2009, Haematologica.
[93] J. Hainsworth,et al. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[94] Valeria Santini,et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. , 2009, The Lancet. Oncology.
[95] E. Estey,et al. Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. , 2009, Blood.
[96] J. Gabrilove,et al. Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes , 2008, British journal of haematology.
[97] M. Cazzola,et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[98] H. Dombret,et al. Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide. , 2008, Leukemia research.
[99] H. Dombret,et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. , 2008, Blood.
[100] H. Deeg,et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[101] U. Germing,et al. Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high‐risk karyotypes , 2007, Cancer.
[102] J. Perfect,et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. , 2007, The New England journal of medicine.
[103] U. Germing,et al. Myelodysplastic syndromes in patients younger than age 50. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[104] B. Cheson,et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.
[105] L. Mannone,et al. High‐dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study , 2006, British journal of haematology.
[106] John M Bennett,et al. Decitabine improves patient outcomes in myelodysplastic syndromes , 2006, Cancer.
[107] E. Estey,et al. Long‐term follow‐up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome , 2006, Cancer.
[108] M. Tormo,et al. Darbepoetin alpha for the treatment of anemia in patients with myelodysplastic syndromes. , 2006, Cancer.
[109] E. Estey,et al. Results of Intensive Chemotherapy in 998 Patients Aged 65 Years or Older with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome - Predictive Prognostic Models for Outcome. , 2005 .
[110] Luca Malcovati,et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[111] T. S. St. Pierre,et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. , 2005, Blood.
[112] John P Klein,et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. , 2004, Blood.
[113] C. Schoch,et al. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31 , 2004, Leukemia.
[114] A. la Sala,et al. Efficacy of a single, weekly dose of recombinant erythropoietin in myelodysplastic syndromes , 2003, British journal of haematology.
[115] Guidelines for the use of platelet transfusions , 2003, British journal of haematology.
[116] H. Eiskjaer,et al. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. , 2003, Blood.
[117] I. Dybedal,et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony‐stimulating factor: significant effects on quality of life , 2003, British journal of haematology.
[118] G. Mufti,et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes , 2003, British journal of haematology.
[119] D N Firmin,et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. , 2001, European heart journal.
[120] M. Sagmeister,et al. A restrictive platelet transfusion policy allowing long-term support of outpatients with severe aplastic anemia. , 1999, Blood.
[121] E. Wattel,et al. Long‐term follow‐up of de novo myelodysplastic syndromes treated with intensive chemotherapy: incidence of long‐term survivors and outcome of partial responders , 1997, British journal of haematology.
[122] K. Kojima,et al. Low-dose melphalan for treatment of high-risk myelodysplastic syndromes. , 1996, Leukemia.
[123] W. Crosby,et al. Regulation of the Intestinal Absorption of Iron by the Rate of Erythropoiesis , 1965, British journal of haematology.